Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity

Kidney International

Volumn 73, Issue 11, 2008, Pages 1231-1239

  Xiao, Y ^a,b   Ge, M ^c   Xue, X ^a,b   Wang, C ^b   Wang, H ^a   Wu, X ^a,b   Li, L ^b   Liu, L ^a,b   Qi, X ^a,b   Zhang, Y ^a,b   Li, Y ^a,b   Luo, H ^d   Xie, T ^c   Gu, J ^d,e   Ren, J ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Shanghai TenGen Biomedical Co Ltd   (China)

^d UNIVERSITY AT ALBANY   (United States)

^e WADSWORTH CENTER   (United States)

Author keywords

Aristolochic acid nephropathy; CPR null mice; CYP1A; Kidney toxicity; Metabolism

Indexed keywords

3 METHYLCHOLANTHRENE; ARISTOLACTAM I; ARISTOLOCHIC ACID; CYTOCHROME P450 1A; LACTAM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DETOXIFICATION; DRUG CLEARANCE; ENZYME INDUCTION; HUMAN; HUMAN CELL; KIDNEY INJURY; KIDNEY TUBULE CELL; LETHAL DOSE; LIVER LEVEL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; NOTE; NULL ALLELE; PRIORITY JOURNAL; RENAL PROTECTION; SURVIVAL RATE; TISSUE LEVEL; TOXICITY TESTING; WILD TYPE;

EID: 43749122582     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.103     Document Type: Article

References (39)

1. J.L. Vanherweghem M. Depierreux C. Tielemans Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs Lancet 341 1993 387 391
2. J.L. Nortier J.L. Vanherweghem For patients taking herbal therapy—lessons from aristolochic acid nephropathy Nephrol Dial Transplant 22 2007 1512 1517
3. V.M. Arlt M. Stiborova H.H. Schmeiser Aristolochic acid as a probable human cancer hazard in herbal remedies: a review Mutagenesis 17 2002 265 277
4. A. Pfohl-Leszkowicz T. Petkova-Bocharova I.N. Chernozemsky Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins Food Addit Contam 19 2002 282 302
5. V.M. Arlt D. Ferluga M. Stiborova Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101 2002 500 502
6. M. Vanhaelen R. Vanhaelen-Fastre P. But Identification of aristolochic acid in Chinese herbs Lancet 343 1994 174
7. A.P. Grollman S. Shibutani M. Moriya Aristolochic acid and the etiology of endemic (Balkan) nephropathy Proc Natl Acad Sci USA 104 2007 12129 12134
8. M. Pailer W.G. Kump On the investigation of basic constituents of Achillea species Arch Pharm 293/65 1960 646 654
9. P. Balachandran F. Wei R.C. Lin Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells Kidney Int 67 2005 1797 1805
10. V. Kumar Poonam A.K. Prasad Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities Nat Prod Rep 20 2003 565 583
11. G. Krumbiegel J. Hallensleben W.H. Mennicke Studies on the metabolism of aristolochic acids I and II Xenobiotica 17 1987 981 991
12. M. Stiborova E. Frei M. Wiessler Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2 Chem Res Toxicol 14 2001 1128 1137
13. M. Stiborova E. Frei P. Hodek Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer Int J Cancer 113 2005 189 197
14. M. Stiborova E. Frei A. Breuer Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase–(32)P-postlabeling analysis of DNA adduct formation Mutat Res 493 2001 149 160
15. M. Stiborova E. Frei B. Sopko Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase Carcinogenesis 24 2003 1695 1703
16. P.H. Rooney C. Telfer M.C. McFadyen The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions Curr Cancer Drug Targets 4 2004 257 265
17. J. Gu Y. Weng Q.Y. Zhang Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase J Biol Chem 278 2003 25895 25901
18. C.J. Henderson D.M. Otto D. Carrie Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase J Biol Chem 278 2003 13480 13486
19. C. Fang M. Behr F. Xie Mechanism of chloroform-induced renal toxicity: non-involvement of hepatic cytochrome P450-dependent metabolism Toxicol Appl Pharmacol 227 2008 48 55
20. C.J. Henderson G.J. Pass C.R. Wolf The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity Toxicol Lett 162 2006 111 117
21. G.J. Pass D. Carrie M. Boylan Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse Cancer Res 65 2005 4211 4217
22. J. Gu H. Cui M. Behr In vivo mechanisms of tissue-selective drug toxicity: effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa Mol Pharmacol 67 2005 623 630
23. Y. Ogino T. Itakura R. Mitsuo Induction of two forms of Eel cytochrome P450 1A genes by 3-methylcholanthrene Mar Biotechnol (NY) 1 1999 342 345
24. H.H. Schmeiser C.A. Bieler M. Wiessler Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy Cancer Res 56 1996 2025 2028
25. M. Stiborova B. Sopko P. Hodek The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen Cancer Lett 229 2005 193 204
26. R.D. Finn A.W. McLaren D. Carrie Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system J Pharmacol Exp Ther 322 2007 40 47
27. W. Chan L. Cui G. Xu Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom 20 2006 1755 1760
28. M. Stiborova E. Frei V.M. Arlt Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy Mutat Res 658 2008 55 67
29. Y. Weng C.C. DiRusso A.A. Reilly Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene. Mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype J Biol Chem 280 2005 31686 31698
30. H.H. Schmeiser B.L. Pool M. Wiessler Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver Carcinogenesis 7 1986 59 63
31. X. Qi Y. Cai L. Gong Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid Toxicol Appl Pharmacol 222 2007 105 110
32. R.C. Fernando H.H. Schmeiser H.R. Scherf Formation and persistence of specific purine DNA adducts by 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I IARC Sci Publ 124 1993 167 171
33. J.L. Nortier H.H. Schmeiser M.C. Muniz Martinez Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure Nephrol Dial Transplant 18 2003 426 428
34. H. Autrup Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response Mutat Res 464 2000 65 76
35. D.L. Eaton E.P. Gallagher T.K. Bammler Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity Pharmacogenetics 5 1995 259 274
36. L. Wu J. Gu H. Cui Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450 J Pharmacol Exp Ther 312 2005 35 43
37. S.M. Chen M.Y. Fan C.C. Tseng Pharmacokinetics and nephrotoxicity of aristolochic acid in rabbits Toxicon 50 2007 180 188
38. J. Yuan Q. Liu G. Wei Characterization and determination of six aristolochic acids and three aristololactams in medicinal plants and their preparations by high-performance liquid chromatography-photodiode array detection/electrospray ionization mass spectrometry Rapid Commun Mass Spectrom 21 2007 2332 2342
39. M.D. Burke S. Thompson C.R. Elcombe Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450 Biochem Pharmacol 34 1985 3337 3345